Publication

Number of items: 11.
31 October 2025
  • Safety of factor XI inhibitors compared to factor X inhibitors in atrial fibrillation: a systematic review and meta-analysis. (2025) Rafaella I. L. Markides, Sogol Koolaji, Joshua H. Leader, Mohamed Farag and Diana A. Gorog
    • 28 May 2021
  • Incidence of thrombotic complications in COVID-19. (2021) William Jenner and Diana Gorog
    • 21 May 2021
  • Screening for venos thromboembolism in patient with COVID-19. (2021) Christophe Vandenbriele and Diana Gorog
    • 1 April 2021
  • Thrombotic complications in 2,928 patients with COVID-19 treated in intensive care: a systematic review. (2021) William Jenner, Rahim Kanji, Saeed Mirsadraee, Ying X. Gue, Susanna Price, Sanjay Prasad and Diana Gorog description
    • 11 June 2020
  • Point-of-care Platelet Function Tests: Relevance to Arterial Thrombosis and Opportunities for Improvement. (2020) Diana Gorog and Richard Becker
    • 23 December 2019
  • Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome. (2019) Ying X Gue, Rahim Kanji, David M Wellsted, Manivannan Srinivasan, Solange Wyatt and Diana A Gorog
    • 1 November 2019
  • MINOCA presenting with STEMI – incidence, aetiology and outcome in a contemporaneous cohort. (2019) Ying X. Gue, Natasha Corballis, Alisdair Ryding, Juan Carlos Kaski and Diana Gorog
    • 1 April 2019
  • Impaired endogenous fibrinolysis at high shear using a point-of-care test in STEMI is associated with alterations in clot architecture. (2019) Nikolaos Spinthakis, Ying Gue, Mohamed Farag, Guogang Ren, Manivannan Srinivasan, Anwar Baydoun and Diana A Gorog
    • 1 May 2018
  • Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications. (2018) Diana Gorog
    • 1 November 2017
  • Catheter ablation for AF improves global thrombotic profile and enhances fibrinolysis. (2017) Maria Niespialowska-Steuden, Vias Markides, Mohamed Farag, David Jones, Wajid Hussain, Tom Wong and Diana A Gorog
    • November 2014
  • PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. (2014) G. Rosser, P. Tricoci, D. Morrow, C. Christopoulos, M. Niespialowska-Steuden, Robert Kozarski, R. Wilcox and Diana Gorog picture_as_pdf